ERBB2 and breast cancer: In a cohort of 775 patients with pathological non-pCR breast cancer after neoadjuvant therapy, HER2-low expressing breast cancers accounted for almost more than half (59.61%) of the entire HER2-negative cohort, which is consistent with available research data (8).